{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:49:29Z","timestamp":1793396969745,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jhepr.2025.101436","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T02:04:52Z","timestamp":1746151492000},"page":"101436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology"],"prefix":"10.1016","volume":"7","author":[{"given":"Dana","family":"Ivancovsky Wajcman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1841-8133","authenticated-orcid":false,"given":"Aina","family":"Nicol\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-662X","authenticated-orcid":false,"given":"Camila A.","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"van Selm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4476","authenticated-orcid":false,"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-3526","authenticated-orcid":false,"given":"Saleh A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homie","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-7508","authenticated-orcid":false,"given":"Massimo G.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Kautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2025.101436_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101436_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2025.101436_bib4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhepr.2025.101436_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib8","unstructured":"SDG Indicators \u2013 global indicator framework for the Sustainable Development Goals and targets of the 2030 Agenda for Sustainable Development. New York: United Nations Statistics Division (UNSD). Available from: https:\/\/unstats.un.org\/sdgs\/indicators\/Global%20Indicator%20Framework%20after%202020%20review_Eng.pdf."},{"key":"10.1016\/j.jhepr.2025.101436_bib9","series-title":"Global hepatitis report 2024. Action for access in low- and middle-income countries","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101436_bib10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib13","author":"Wild"},{"key":"10.1016\/j.jhepr.2025.101436_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101436_bib15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib17","first-page":"2","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & hepatology commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib19","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/vaccines10050793","article-title":"The global impact of hepatitis B vaccination on hepatocellular carcinoma","volume":"10","author":"Flores","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jhepr.2025.101436_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000188","article-title":"HBV eradication from the host: current understanding and challenges","volume":"23","author":"Mbelle","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215652","article-title":"Long term outcome of prevention of liver cancer by hepatitis B vaccine: results from an RCT with 37 years","volume":"536","author":"Cao","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2025.101436_bib23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2025.101436_bib24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2016.04.030","article-title":"Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan","volume":"14","author":"Ni","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-14-754","article-title":"Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10900-014-9975-y","article-title":"HBV outreach programs significantly increase knowledge and vaccination rates among Asian pacific islanders","volume":"40","author":"Zacharias","year":"2015","journal-title":"J Community Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib27","series-title":"Opportunities to offer harm reduction to people who inject drugs during infectious disease encounters: narrative review. Open forum infectious diseases","first-page":"ofaa503","volume":"2020","author":"Peckham","year":"2020"},{"key":"10.1016\/j.jhepr.2025.101436_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001332","article-title":"Barriers and facilitators to hepatitis B birth dose vaccination: perspectives from healthcare providers and pregnant women accessing antenatal care in Nigeria","volume":"3","author":"Freeland","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12879-024-09326-9","article-title":"Low HBV knowledge is associated with low HBV vaccination uptake in general adult population despite incentivization of HBV vaccination","volume":"24","author":"Kim","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib31","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/ijerph16111958","article-title":"Gaps in HCV knowledge and risk behaviors among young suburban people who inject drugs","volume":"16","author":"Jost","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","article-title":"Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs\u2013a scoping review of the qualitative evidence","volume":"23","author":"Balsom","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jvh.13604","article-title":"Hepatitis B screening among immigrants: how to successfully reach the Moroccan community","volume":"28","author":"Hamdiui","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2025.101436_bib34","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v22.i25.5837","article-title":"Towards safe injection practices for prevention of hepatitis C transmission in South Asia: challenges and progress","volume":"22","author":"Janjua","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101436_bib36","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41467-021-26475-6","article-title":"The impact of the timely birth dose vaccine on the global elimination of hepatitis B","volume":"12","author":"de Villiers","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101436_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib38","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/IJWH.S326293","article-title":"Why women in Ethiopia give birth at home? A systematic review of literature","author":"Weldegiorgis","year":"2021","journal-title":"Int J Women's Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib39","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1016\/S2214-109X(20)30231-X","article-title":"Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study","volume":"8","author":"Seaman","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib40","article-title":"Hepatitis B vaccination status among health care workers in a tertiary hospital in Ethiopia","volume":"2017","author":"Biset Ayalew","year":"2017","journal-title":"Hepat Res Treat"},{"key":"10.1016\/j.jhepr.2025.101436_bib41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12889-024-18330-2","article-title":"Prevalence and factors associated with hepatitis b vaccination uptake and completion among communities targeted for mass vaccination in gulu: a cross-sectional study","volume":"24","author":"Kimera","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines11020398","article-title":"Barriers to and facilitators of hepatitis B vaccination among the adult population in Indonesia: a mixed methods study","volume":"11","author":"Machmud","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jhepr.2025.101436_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10900-019-00723-9","article-title":"Vaccine-hesitant and vaccine-refusing parents\u2019 reflections on the way parenthood changed their attitudes to vaccination","volume":"45","author":"Rozbroj","year":"2020","journal-title":"J Community Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/21645515.2016.1264549","article-title":"Negative perceptions of hepatitis B vaccination among attendees of an urban free testing center for sexually transmitted infections in France","volume":"13","author":"Moyroud","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhepr.2025.101436_bib45","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.aohep.2020.06.003","article-title":"Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma","volume":"19","author":"Pinero","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2025.101436_bib51","series-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023"},{"key":"10.1016\/j.jhepr.2025.101436_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/pathogens13080681","article-title":"Hepatitis C elimination in Egypt: story of success","volume":"13","author":"Gomaa","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.jhepr.2025.101436_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/v12080815","article-title":"Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead","volume":"12","author":"Liu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2025.101436_bib56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib57","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/cid\/ciad126","article-title":"Reflex hepatitis C virus viral load testing following an initial positive hepatitis C virus antibody test: a global systematic review and meta-analysis","volume":"77","author":"Tao","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib58","article-title":"Implementing a new HCV model of care for people who use drugs","author":"Mochales","year":"2024","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101436_bib59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/a-1777-6112","article-title":"A global systematic review of hepatitis C elimination efforts through micro-elimination","volume":"42","author":"Lazarus","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104185","article-title":"Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark","volume":"121","author":"Demant","year":"2023","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhepr.2025.101436_bib61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s43856-023-00420-8","article-title":"Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain","volume":"3","author":"Picchio","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.jhepr.2025.101436_bib62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s44263-023-00026-1","article-title":"A new approach to prevent, diagnose, and treat hepatitis B in Africa","volume":"1","author":"Spearman","year":"2023","journal-title":"BMC Glob Public Health"},{"key":"10.1016\/j.jhepr.2025.101436_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhep.2014.10.008","article-title":"Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach","volume":"62","author":"Lemoine","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S2468-1253(24)00308-X","article-title":"Availability of point-of-care HBV tests in resource-limited settings","volume":"9","author":"Lau","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib65","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","article-title":"Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments","volume":"1","author":"Wait","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4254\/wjh.v16.i8.1091","article-title":"Bridging the gap: addressing disparities in hepatitis C screening, access to care, and treatment outcomes","volume":"16","author":"Alenzi","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40249-024-01225-0","article-title":"Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review","volume":"13","author":"Li","year":"2024","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.jhepr.2025.101436_bib68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-019-0177-z","article-title":"Too many people with viral hepatitis are diagnosed late\u2014with dire consequences","volume":"16","author":"Lazarus","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib69","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib70","article-title":"Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data","volume":"10","author":"Doyle","year":"2020","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2025.101436_bib71","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101436_bib72","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2021.11.023","article-title":"Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules","volume":"76","author":"Sanduzzi-Zamparelli","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib73","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib74","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101436_bib75","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S2468-1253(20)30238-7","article-title":"The impact of COVID-19 on hepatitis elimination","volume":"5","author":"Wingrove","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib76","series-title":"Global report on infection prevention and control 2024","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101436_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib78","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101436_bib79","doi-asserted-by":"crossref","first-page":"djv359","DOI":"10.1093\/jnci\/djv359","article-title":"Hepatitis-associated liver cancer: gaps and opportunities to improve care","volume":"108","author":"McMahon","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.jhepr.2025.101436_bib84","article-title":"Viral hepatitis as a risk factor for the development of hepatocellular carcinoma","volume":"6","author":"Alqahtani","year":"2020","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jhepr.2025.101436_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814404","article-title":"Hepatocellular carcinoma prevention in the era of hepatitis c elimination","volume":"24","author":"Lazarus","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2025.101436_bib86","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.334.6063.1628","article-title":"Breakthrough of the year. HIV treatment as prevention","volume":"334","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101436_bib87","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","author":"Hajarizadeh","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib88","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib89","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1478-3231.2008.01816.x","article-title":"Preventative hepatology: minimising symptoms and optimising care","volume":"28","author":"Hirschfield","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib90","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","author":"Razavi","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101436_bib92","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib93","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib94","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","article-title":"EASL position paper on clinical follow-up after HCV cure","volume":"81","author":"Reiberger","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib95","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jfma.2024.01.015","article-title":"Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment","volume":"123","author":"Maekawa","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jhepr.2025.101436_bib96","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers12061351","article-title":"Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics","volume":"12","author":"Rinaldi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2025.101436_bib97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: new therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib98","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101436_bib99","series-title":"Open forum infectious diseases","article-title":"HIV infection and the risk of hepatocellular carcinoma in patients with hepatitis B virus (HBV) Co-infection: a propensity score-matched cohort study","author":"Lui","year":"2019"},{"key":"10.1016\/j.jhepr.2025.101436_bib100","series-title":"The liver meeting digital experience","article-title":"Risk of HCC in patients with HBV infection with and without HIV co-infection: a US administrative claims analysis","author":"Naggie","year":"2020"},{"key":"10.1016\/j.jhepr.2025.101436_bib101","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1111\/hepr.12743","article-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2025.101436_bib102","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos (t) ide analogue-naive HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials","volume":"98","author":"Cai","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.jhepr.2025.101436_bib103","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jgh.15783","article-title":"Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis","volume":"37","author":"Yuan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib104","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101436_bib105","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib106","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib107","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2025.101436_bib108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/liv.15253","article-title":"Hepatocellular carcinoma: the virus or the liver?","volume":"43","author":"Papatheodoridi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib110","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib111","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/pathogens13050362","article-title":"Hepatitis delta virus and hepatocellular carcinoma","volume":"13","author":"Lombardo","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.jhepr.2025.101436_bib112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101436_bib113","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S2468-1253(23)00074-2","article-title":"Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study","volume":"8","author":"Nayagam","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib114","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(21)00475-1","article-title":"A call for advocacy and patient voice to eliminate hepatitis B virus infection","volume":"7","author":"Matthews","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib116","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib117","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib118","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S2468-1253(22)00041-3","article-title":"Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa","volume":"7","author":"Spearman","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib119","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2017.04.41","article-title":"Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease","volume":"5","author":"Mantovani","year":"2017","journal-title":"Ann Translational Med"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101436_bib120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","article-title":"Inequities in primary liver cancer in Europe: the state of play","volume":"80","author":"Kondili","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib121","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib122","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/liv.15252","article-title":"Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia","volume":"42","author":"Yang","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101436_bib123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/apt.16706","article-title":"Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver","volume":"55","author":"Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101436_bib124","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/MCG.0000000000001217","article-title":"Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B","volume":"54","author":"Cho","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101436_bib125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/apt.15575","article-title":"Systematic review: chronic viral hepatitis and metabolic derangement","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101436_bib126","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/hep.32792","article-title":"Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis","volume":"77","author":"Mao","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101436_bib127","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/alcalc\/agz102","article-title":"Meta-Analysis of the prevalence of HBV infection among alcohol users worldwide","volume":"55","author":"Magri","year":"2020","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.jhepr.2025.101436_bib128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ijc.30782","article-title":"Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers","volume":"141","author":"Chu","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhepr.2025.101436_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247281","article-title":"Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data","volume":"16","author":"Kimanya","year":"2021","journal-title":"Plos One"},{"key":"10.1016\/j.jhepr.2025.101436_bib130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med"},{"key":"10.1016\/j.jhepr.2025.101436_bib131","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101436_bib132","doi-asserted-by":"crossref","DOI":"10.15403\/jgld-805","article-title":"Inverse association of coffee with liver cancer development: an updated systematic review and meta-analysis","volume":"29","author":"Bhurwal","year":"2020","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101436_bib133","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41416-020-0741-x","article-title":"Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies","volume":"122","author":"Zhang","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2025.101436_bib134","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/nu13010172","article-title":"The association between diet and hepatocellular carcinoma: a systematic review","volume":"13","author":"George","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jhepr.2025.101436_bib135","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib136","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers14010103","article-title":"Lifestyle and hepatocellular carcinoma what is the evidence and prevention recommendations","volume":"14","author":"Zelber-Sagi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2025.101436_bib137","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ajcn\/nqab124","article-title":"Grading nutrition evidence: where to go from here?","volume":"113","author":"Tobias","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101436_bib138","first-page":"CD013156","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"6","author":"Buzzetti","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhepr.2025.101436_bib139","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.108170","article-title":"Common limitations and challenges of dietary clinical trials for translation into clinical practices","volume":"19","author":"Mirmiran","year":"2021","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2025.101436_bib140","article-title":"Prevention of hepatitis B virus-related hepatocellular carcinoma","volume":"7","author":"Lin","year":"2021","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jhepr.2025.101436_bib141","doi-asserted-by":"crossref","DOI":"10.12998\/wjcc.v9.i33.10052","article-title":"Effects of alcohol consumption on viral hepatitis B and C","volume":"9","author":"Xu","year":"2021","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101436_bib142","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib143","first-page":"771","article-title":"Editorial: Unsilencing liver disease","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101436_bib144","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:08:21Z","timestamp":1755245301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":132,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589555925001132"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101436","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101436"}}